Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data

@article{Sundstrm2014BloodPT,
  title={Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data},
  author={Johan Sundstr{\"o}m and Hisatomi Arima and Mark Woodward and Rod Jackson and Kunal N. Karmali and Donald M. Lloyd‐Jones and Colin Baigent and Jonathan R. Emberson and Kazem Rahimi and Stephen MacMahon and Anushka Patel and Vlado Perkovic and Fiona M Turnbull and Bruce Neal},
  journal={The Lancet},
  year={2014},
  volume={384},
  pages={591-598}
}
BACKGROUND We aimed to investigate whether the benefits of blood pressure-lowering drugs are proportional to baseline cardiovascular risk, to establish whether absolute risk could be used to inform treatment decisions for blood pressure-lowering therapy, as is recommended for lipid-lowering therapy. METHODS This meta-analysis included individual participant data from trials that randomly assigned patients to either blood pressure-lowering drugs or placebo, or to more intensive or less… Expand
Effectiveness of blood pressure-lowering drug treatment by levels of absolute risk: post hoc analysis of the Australian National Blood Pressure Study
TLDR
It is confirmed that the benefit of treatment was substantial only in the high-risk tertile, reaffirming the rationale of treating elevated blood pressure in the setting of all risk factors rather than in isolation. Expand
Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis
  • Amanda Larry Ale Folkert W Nigel S Eivind Henry Frank P J Adler Agodoa Algra Asselbergs Beckett Berge Black , A. Adler, +89 authors Jiguang Wang
  • Medicine
  • The Lancet
  • 2021
TLDR
In this large-scale analysis of randomised trials, a 5 mm Hg reduction of systolic blood pressure reduced the risk of major cardiovascular events by about 10%, irrespective of previous diagnoses of cardiovascular disease, and even at normal or high–normal blood pressure values. Expand
Blood pressure-lowering treatment strategies based on cardiovascular risk versus blood pressure: A meta-analysis of individual participant data
TLDR
A blood pressure-lowering treatment strategy based on predicted cardiovascular risk is more effective than one based on blood pressure levels alone across a range of thresholds and support using cardiovascular risk assessment to guide blood pressure treatment decision-making in moderate- to high-risk individuals, particularly for primary prevention. Expand
Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials
TLDR
This analysis assessed the associations between mean blood pressure achieved on treatment; prerandomisation baseline blood pressure; or time-updated blood pressure on the composite outcome of cardiovascular death, myocardial infarction, stroke, and hospital admission for heart failure; the components of the Composite outcome; and all-cause death. Expand
The case for absolute cardiovascular risk-based blood pressure-lowering treatment decisions: data from the SPRINT trial
TLDR
This analysis of the SPRINT trial found that the CVD-risk strategy resulted in a greater number of cardiovascular events avoided per persons treated than the SBP strategy, across a wide range of potential treatment thresholds including below 140 mmHg. Expand
Eligibility and subsequent burden of cardiovascular disease of four strategies for blood pressure-lowering treatment: a retrospective cohort study
TLDR
A cardiovascular risk-based strategy (QRISK2 ≥10%) could prevent over a third more cardiovascular disease events than the 2011 NICE guideline and a fifth more than the 2019 NICE guidelines, with similar efficiency regarding number treated per event avoided. Expand
Effect of intensive blood pressure lowering on cardiovascular outcomes based on cardiovascular risk: A secondary analysis of the SPRINT trial
TLDR
Intensive systolic blood pressure reduction is beneficial for primary prevention of cardiovascular morbidity and mortality in patients without diabetes with more than low cardiac risk (above 10%). Expand
Individualizing treatment choices in the systolic blood pressure intervention trial
TLDR
Having adverse events has less weight when it comes to therapeutic decisions and antihypertensive therapy intensification is beneficial for the great majority of patients included in the systolic blood pressure intervention trial. Expand
Synergistic effects of blood pressure-lowering drugs and statins: systematic review and meta-analysis
TLDR
The combined relative effects of blood pressure-lowering drugs and statins on cardiovascular events were multiplicative, which supports risk-based treatment decision strategies and fixed-combination polypills. Expand
Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses
TLDR
Antihypertensive treatment reduces the risk of mortality and cardiovascular morbidity in people with diabetes mellitus and a systolic blood pressure more than 140 mm Hg, however, further treatment is associated with an increased risk of cardiovascular death, with no observed benefit. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 62 REFERENCES
Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials
TLDR
There were no significant differences in total major cardiovascular events between regimens based on ACE inhibitors, calcium antagonists, or diuretics or beta blockers, although ACE-inhibitor-based regimens reduced blood pressure less. Expand
Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies
TLDR
All the classes of blood pressure lowering drugs have a similar effect in reducing CHD events and stroke for a given reduction in blood pressure, indicating that the benefit is explained by blood pressure reduction itself. Expand
Estimating treatment effects for individual patients based on the results of randomised clinical trials
Objectives To predict treatment effects for individual patients based on data from randomised trials, taking rosuvastatin treatment in the primary prevention of cardiovascular disease as an example,Expand
Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk
TLDR
The rationale for targeting blood pressure and blood cholesterol lowering drug treatments to patients at high absolute cardiovascular risk, irrespective of their blood pressure or blood cholesterol levels is outlined. Expand
Cost-Effectiveness Analysis of Hypertension Guidelines in South Africa: Absolute Risk Versus Blood Pressure Level
TLDR
Current guidelinesbased on blood pressure levels are both more expensive and less effective than guidelines based on absolute risk of cardiovascular disease in South Africa, which could free up major resources for other pressing needs, especially in developing countries. Expand
Protocol for prospective collaborative overviews of major randomized trials of blood-pressure-lowering treatments. World Health Organization-International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration.
TLDR
The combination of trial results in prospectively planned, systematic overviews both reduces random errors and avoids biases and should provide more reliable information about the effects of newer blood-pressure-lowering drugs than would any one study alone. Expand
Randomised trial of a perindopril-based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack
TLDR
This blood-pressure-lowering regimen reduced the risk of stroke among both hypertensive and non-hypertensive individuals with a history of stroke or transient ischaemic attack, irrespective of their blood pressure. Expand
The effects of blood pressure reduction in older patients: an overview of five randomized controlled trials in elderly hypertensives.
TLDR
The results suggest that over 10 years, treatment would prevent at least one major vascular event among every 10 elderly patients at similar risk to those enrolled in the trials. Expand
Blood pressure-dependent and independent effects of agents that inhibit the renin–angiotensin system
TLDR
There are similar blood pressure-dependent effects of ACEI and ARB for the risks of stroke, CHD and heart failure and for ACEI, but not ARB, there is evidence ofBlood pressure-independent effects on the risk of major coronary disease events. Expand
Improving the cost-effectiveness of cardiovascular disease prevention in Australia: a modelling study
TLDR
Changing to absolute risk-based cardiovascular disease prevention is highly recommended for reducing health sector spending, but the Australian Government must also consider measures to reduce the cost of statin drugs, over and above the legislated price cuts of November 2010. Expand
...
1
2
3
4
5
...